Aortic Valve Predilatation with a Small Balloon, without Rapid Pacing, prior to Transfemoral Transcatheter Aortic Valve Replacement

  • Anupama Shivaraju
    Deutsches Herzzentrum München, Department for Cardiovascular Diseases, Technische Universität München, Lazarettstr. 36, 80636 Munich, Germany
  • Christian Thilo
    Department of Cardiology, Klinikum Augsburg, Herzzentrum Augsburg-Schwaben, Stenglinstr. 2, 86156 Augsburg, Germany
  • Neal Sawlani
    Department of Cardiology, Advocate Christ Medical Center, 4440 W. 95th Street, Oak Lawn, IL, USA
  • Ilka Ott
    Deutsches Herzzentrum München, Department for Cardiovascular Diseases, Technische Universität München, Lazarettstr. 36, 80636 Munich, Germany
  • Heribert Schunkert
    Deutsches Herzzentrum München, Department for Cardiovascular Diseases, Technische Universität München, Lazarettstr. 36, 80636 Munich, Germany
  • Wolfgang von Scheidt
    Department of Cardiology, Klinikum Augsburg, Herzzentrum Augsburg-Schwaben, Stenglinstr. 2, 86156 Augsburg, Germany
  • Adnan Kastrati
    Deutsches Herzzentrum München, Department for Cardiovascular Diseases, Technische Universität München, Lazarettstr. 36, 80636 Munich, Germany
  • Albert Markus Kasel
    Deutsches Herzzentrum München, Department for Cardiovascular Diseases, Technische Universität München, Lazarettstr. 36, 80636 Munich, Germany

この論文をさがす

説明

<jats:p><jats:italic>Objectives.</jats:italic> The aim of this study is to assess the feasibility and clinical outcome of transcatheter aortic valve replacement (TAVR) using aortic valve predilatation (AVPD) with a small, nonocclusive balloon.<jats:italic> Background.</jats:italic> Balloon aortic valvuloplasty (BAV) under rapid pacing is generally performed in TAVR to ensure the passage and sufficient deployment of the prosthesis in the stenotic AV. BAV may cause serious complications, such as left ventricular stunning or cerebrovascular embolism.<jats:italic> Methods.</jats:italic> A cohort of 50 consecutive patients with severe aortic stenosis underwent transfemoral TAVR with the Edwards Sapien 3-heart valve. All patients underwent AVPD with a small, nonocclusive balloon (12 × 60 or 14 × 60 mm) without rapid pacing. Procedural data and clinical outcomes were analyzed.<jats:italic> Results.</jats:italic> The mean age of the cohort was <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mn fontstyle="italic">81</mml:mn><mml:mo>±</mml:mo><mml:mn fontstyle="italic">6</mml:mn></mml:math> years and the mean logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) was <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mn fontstyle="italic">13</mml:mn><mml:mo>±</mml:mo><mml:mn fontstyle="italic">9</mml:mn></mml:math>. Crossing the AV and prosthesis implantation was successful in all cases. The postprocedural mean AV gradient was <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mn fontstyle="italic">12</mml:mn><mml:mo>±</mml:mo><mml:mn fontstyle="italic">5</mml:mn></mml:math> mmHg. There were no cases of aortic regurgitation ≥ grade 2. No periprocedural stroke occurred. One patient (2%) with chronic atrial fibrillation displayed a transient Wernicke aphasia occurring more than 24 hours after TAVR. Mortality was 0% at 30 days after procedure.<jats:italic> Conclusion.</jats:italic> In TAVR, AVPD with a small, nonocclusive balloon can be safely performed. By avoiding rapid pacing, this technique may be a valid alternative to traditional BAV. Whether or not the use of APVD without rapid pacing translates into less periprocedural complications needs to be assessed in future studies.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ